Regulation Impact Statement Updates

Official website for publishing regulatory impact analysis information for regulatory decisions announced by the Australian Government, COAG and COAG Councils.

Access to cannabis for medical and scientific purposes

Aust Gov
31st March 2016

Regulation Impact Statement – Department of Health

On 10 February 2016 the Minister for Health announced amendments to the Narcotic Drugs Act 1967 to enable the cultivation of cannabis for medicinal and scientific purposes consistent with Australia’s international obligations while facilitating the production of medicinal cannabis products for clinical trials and for specified patients under clinical care in accordance with the Therapeutic Goods Act 1989.

The measures provide for the establishment of a Commonwealth licensing scheme to facilitate the right to cultivate cannabis for medicinal and scientific purposes.

The Office of Best Practice Regulation assessed the RIS prepared by the Department Health as compliant with the Government’s requirements but not best practice. To achieve best practice more detailed analysis of the practical impacts of the measure and more extensive consultation was required.

The RIS estimates the average annual regulatory cost of the proposal to be $407,000. The OBPR has agreed to the regulatory costs.

Back to all Updates